Cryptogenic Stroke: The role of silent Atrial Fibrillation

Size: px
Start display at page:

Download "Cryptogenic Stroke: The role of silent Atrial Fibrillation"

Transcription

1 Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany 1 Turin,

2 Agenda 1. What is a cryptogenic? stroke Understanding the burden of cryptogenic stroke for individual patients and for society 2. Why bother with paroxysmal Atrial Fibrillation (AF)? 3. How to reliably detect (rare episodes of) paroxysmal AF? Strategies Can we predict paroxysmal AF? 4. What to do then? discussion 2 Turin,

3 Cardio-embolic stroke What is a cryptogenic stroke? Stroke classification according to TOAST Atrial fibrillation, criteria Ventricular aneurysm / thrombus etc. ~30% atherothrombosis Lacunar stroke Carotid stenosis / intracranial stenosis > 50% Aortic plaques, instable carotid plaque? ~15% Cerebral microangiopathy (Hypertension, Diabetes) ~15% Other defined etiologies Periprocedural, dissections, vasculitis, PFO, etc. ~10% Undetermined etiology Concurring etiologies, incomplete work-up cryptogenic strokes ~30% 3 Turin, Adams HP Jr, et. Al. Stroke. 1993;24:35-41.

4 What is a cryptogenic stroke? And understanding the burden of it A cryptogenic stroke is a stroke of unknown cause. The diagnosis demands a thorough and complete work-up of embolic or thrombotic sources 20-30% of all strokes have to be labeled as cryptogenic. That is about Germans or Italians each year! The diagnosis leaves doctors and patients unsure of the risk of future stroke and optimal secondary prevention big psychological problem! We suspect that a number of these patients does have AF we did not detect. 4 Turin,

5 Why bother with paroxysmal atrial fibrillation? Because risk of stroke does not differ greatly between paroxysmal or permanent AF! 1981 patients, Follow-up: 3.6 years Incidence rate of ischemic stroke: Cumulative 2,6% (paf) vs. 2,9% (caf) per year 5 Turin, Friberg L, et al. Eur Heart Journal 2009

6 How to track (rare episodes of) paroxysmal AF? Simple answer: Increase the time of monitoring! Do Holter ECG! Repeat Holter Do telemetry while in hospital! Do 3-7 day Holter Use external loop recorder (MCOT) Do continuous Monitoring (implantable cardiac monitors, ICM) 6 Turin,

7 Study overview: Detection rates of iaf with extended monitoring methods Definition of iaf varied widely In many studies episodes <30s of AF were accepted, and accounted for >50% of all pt.! 7 Turin, Khan M, Miller DJ. Detection of paroxysmal atrial fibrillation in stroke/tia patients. Stroke Res Treat. 2013;2013:

8 Increased monitoring times after stroke result in higher yields of silent AF! Stahrenberg R. Stroke. 2010; 41: Gladstone DJ. NEJM. 2014; 370;26: 2467 Only 69% of patients tolerated the device 5 days or more! Only 4 out of 5 patients had data for 21 days or more! 8 Turin,

9 Prolonged Monitoring = higher Yield Comparison studies in stroke patients Autor n Methodik / Dauer Yield Stahrenberg Stroke d Holter vs. 24h Holter 12,5 % vs. 4,8% Grond Stroke h Holter vs. 24h Holter 4,3% vs. 2,9% Rizios Stroke h stroke unit monitoring (dedicated analysis tool) vs. 24h Holter 7,6% vs. 2,8% Gladstone NEJM d externer loop recorder vs. 24h Holter 16,1% vs. 2,2% Ritter Stroke ICM (Reveal XT ) vs. 7d Holter 17,1% vs. 1,6% 9 Turin,

10 Continuous monitoring has the highest diagnostic yield Implantable cardiac monitors (ICMs) should have the highest yield 10 Turin, Botto G, et al. J Cardiovasc Electrophysiol 2009; 20:

11 ICMs are implanted subcutaneously under local anesthesia e.g.: Reveal XT algorithm detects episodes >2 min. (programmable) XPECT study, : sensitivity (96,1%) and specificity (85,4%) vs. Cardiologist evaluated Holter monitoring in pt. c. known iaf Hindricks G, et al.. Circ Arrhythm Electrophysiol Turin,

12 Pilotstudies using ICMs in cryptogenic stroke patients Autor n Duration of monitoring Median until first episode of iaf Additional Yield Ritter Stroke Median 397 d 64 d 17.1% Cotter Neurology Median 229 d (withoutaf) 48 d 25.5% Etgen Stroke year 153 d 27.3% Christensen Eur J Neurol Mean 569 d Mean 109 (±48) d 16.1% 12 Turin,

13 CRYSTAL-AF, n= Turin, Sanna T., et al: N Engl J Med 2014;370:

14 CRYSTAL AF: Baseline Characteristics: ICM Control Age 61.6 ± 11.4 years 61.4 ± 11.3 years Gender - Male 142 (64.3%) 138 (62.7%) Index Event Stroke 200 (90.5%) 201 (91.4%) Index Event TIA 21 (9.5%) 19 (8.6%) Pre-enrollment AF screening Holter Monitoring Pre-enrollment AF screening Telemetry Time between index event and randomization Time to randomization and device insertion 71.5% of patients Median of 23 hours (IQR 21-24) 29.9% of patients Median of 48 hours (IQR 36-96) 70.9% of patients Median of 24 hours (IQR 22-24) 29.5% of patients Median of 72 hours (IQR 48-96) 36.6 ±28.2 days 39.6 ±26.9 days 8.7 ± 27.6 days n/a 14 Turin,

15 CRYSTAL AF, Secondary Endpoint: Detection of AF at 12 months 12,4% 2,0% 15 Turin, Sanna T., et al: N Engl J Med 2014;370:

16 Can we predict iaf? Can we select the ideal patient for prolonged monitoring? - Clinical predictors: - age - CHADS 2 andcha 2 DS 2 -Vasc Score - Echoparameters: - E.g. atrial size - ECG parameters - e.g. SPBs 16 Turin,

17 Predict iaf by clinical scores? no significant clinical predictors in our study noaf (n=50) iaf (n=10) age 61; ; n.s. Female % (n) 40 (20) 60 (6) n.s. Hypertension % (n) 70 (35) 70 (7) n.s. Diabetes % (n) 14 (7) 0 p=0.1 CHF % (n) 0 0 n.s. Vascular disease % (n) 8 (4) 0 n.s. CHADS 2 -Score 3; 2-3 3; n.s. CHA 2 DS 2 -VASC Score 4; 3-5 4; 3-5 n.s. Insular cortex involvement 14 (7) 10 (1) n.s. Total monitoring time[d] Time to implantation after event [d] 397; ; ; ; n.s. n.s. 17 Turin, Ritter MA et al.; Stroke 2013

18 Cotter et al.: Classical risk factors predict iaf Cotter PE, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology Apr 23;80(17): Turin,

19 Prediction of iaf according to purely clinical risk scores is ineffiecient! 1368 patients screened 416 had AF within 1,1 y. No differences in CHADS 2 - score However: Different population (TRENDS study, known cardiac disease) Different devices (ICD, PM, CRT) 19 Turin, Ziegler PD et al. Am J Cardiol. 2012:110:

20 Subgroup Analysis of CRYSTAL AF: Trend for higher yield of iaf in higher CHADS2 scores 20 Turin,

21 Cotter et al.: Classical risk factors predict iaf - and also echo and ECG parameters! Cotter PE, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology Apr 23;80(17): Turin,

22 22 Turin,

23 Thoughts on consequences for future patient selection for ICMs - 1 ILRs are much more sensitive than 7 day Holter! Most patients detected within 3 mo. from implantation, but there is significant yield beyond this! 7 or 30 days of monitoring are not enough! Emergent questions: How long should a monitoring be performed (in order to attribute a positive result to the recent event)? Is anticoagulation really the answer for all patients with iaf ( AF burden ) How about PFO and iaf? 23 Turin,

24 Thoughts on consequences for future patient selection for ICMs 2 Who is a candidate for extensive monitoring = ICM? Complete work-up performed and stroke is cryptogenic Patients with numerous SBPs and SVRs on 24h Holter You think it s AF (stroke pattern plus risk factors but you can not prove it yet!) Relatively fit patients Compliance with telemetry a lot to lose 24 Turin,

25 Summary % of patients with cryptogenic stroke do have iaf 2. Detection requires at least 3-12 months extensive monitoring 3. It is not possible to predict the occurrence of AF according to clinical risk factors the final word on paraclinical parameters (echo, 24h Holter) has not been spoken 4. Up to now any diagnosis of AF according to cardiological guidelines is currently relevant and should be followed by anticoagulaton 25 Turin,

26 Thank you for your attention! 26 Turin,

ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES

ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January

More information

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

What the general cardiologist should know about arrhythmia Stroke prevention in AF Peter Ammann Kantonsspital St. Gallen What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low

More information

True cryptogenic stroke

True cryptogenic stroke True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures

More information

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria

More information

TOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.

TOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J. TOP 3: EMBRACE N Engl J Med Volume 370(26):2467-2477 June 26, 2014 David J. Gladstone et al Lucy Vieira MD FRCP Neurologist MUHC Receiving research funds AstraZeneca 2014-2016 Original Article Atrial Fibrillation

More information

Diagnosing atrial fibrillation using implantable devices

Diagnosing atrial fibrillation using implantable devices Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC

More information

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.

More information

Speakers. 2015, American Heart Association 1

Speakers. 2015, American Heart Association 1 Speakers Lee Schwamm, MD, FAHA Executive Vice Chairman of Neurology, Massachusetts General Hospital Director, Stroke Service and Medical Director, MGH TeleHealth, Massachusetts General Hospital Director,

More information

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation

More information

Defining Sub-Clinical Atrial Fibrillation and its management

Defining Sub-Clinical Atrial Fibrillation and its management Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical

More information

UTILITY OF THE IMPLANTABLE LOOP RECORDER

UTILITY OF THE IMPLANTABLE LOOP RECORDER UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology

More information

Device detected AF and atrial high rate episodes

Device detected AF and atrial high rate episodes Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular

More information

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο

More information

Causal relationship between AF & stroke

Causal relationship between AF & stroke 7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,

More information

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation 48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December

More information

Cryptogenic Strokes: Evaluation and Management

Cryptogenic Strokes: Evaluation and Management Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG

More information

Causal relationship between AF & stroke

Causal relationship between AF & stroke 7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,

More information

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.

More information

Subclinical AF: Implications of device based episodes

Subclinical AF: Implications of device based episodes Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific

More information

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN

More information

Sixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist

Sixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist 1 One Strategy for cryptogenic stroke: ESUS Positively defined criteria FDA allows clinical trials NOACs have lower risk profile Another strategy

More information

Mohammad Zubaid, MB, ChB, FRCPC, FACC

Mohammad Zubaid, MB, ChB, FRCPC, FACC Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC

More information

Cryptogenic Stroke: A logical approach to a common clinical problem

Cryptogenic Stroke: A logical approach to a common clinical problem Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific

More information

Management of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018

Management of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Management of Atrial Fibrillation Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Disclosures Speaker: St. Jude Medical, Biotronik Consultant: St. Jude Medical, World Care Clinical Objectives Recognize

More information

NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial

NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial R. Wachter a, R. C. Lahno a, B. Haase a, M. Weber-Krüger a,

More information

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart

More information

Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE

Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH

More information

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine

More information

The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study

The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Taya V. Glotzer, MD; Emile G. Daoud, MD; D. George Wyse, MD, PhD; Daniel

More information

Consensus document: Screening and Prevention of Atrial Fibrillation

Consensus document: Screening and Prevention of Atrial Fibrillation Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The

More information

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr

More information

קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן

קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with

More information

How Can We Properly Manage Patients With Stroke of Undetermined Origin?

How Can We Properly Manage Patients With Stroke of Undetermined Origin? How Can We Properly Manage Patients With Stroke of Undetermined Origin? : Spotlight on Embolic Stroke of Undetermined Source (ESUS) MI SUN OH Department of Neurology, Hallym University Scared Heart Hospital,

More information

Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia

Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia Gianluca Botto, FESC Elettrofisiologia Ospedale Sant Anna, Como Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia 20 min Presenter Disclosure Information n n n Research

More information

Medicare Advantage Medical Policy

Medicare Advantage Medical Policy Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Description/Background Indications for Ambulatory Cardiac

More information

CRYPTOGENIC STROKE THERAPY AWARENESS PRESENTATION. Reveal LINQ TM

CRYPTOGENIC STROKE THERAPY AWARENESS PRESENTATION. Reveal LINQ TM CRYPTOGENIC STROKE Reveal LINQ TM Insertable Insertable Cardiac Cardiac Monitoring Monitoring System System THERAPY AWARENESS PRESENTATION Epidemiology Diagnosis Guidelines and Evidence to Support Reveal

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Implantable Cardiac Event Monitors Policy Number: NMP495 Effective Date*: November 2009 Update: May 2016 ARCHIVE: NOTE: This policy has been retired. Please use DME Policy

More information

Cryptogenic Stroke: Finding Light in the Darkness

Cryptogenic Stroke: Finding Light in the Darkness Cryptogenic Stroke: Finding Light in the Darkness Scott E. Kasner, MD Professor of Neurology Director, Comprehensive Stroke Center Disclosures WL Gore PI for Gore REDUCE Trial Medtronic DSMB for CRYSTAL

More information

Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ

Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System www.arrhythmia.org; @drsuneet October 31, 2015

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic

More information

Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment

Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment MAEDICA a Journal of Clinical Medicine 2018; 13(4): 261-265 https://doi.org/10.26574/maedica.2018.13.4.261 Mædica - a Journal of Clinical Medicine Invited Editorial Point of View Subclinical Atrial Fibrillation,

More information

Why to monitor AF ablation success?

Why to monitor AF ablation success? Why to monitor AF ablation success? Why to monitor AF ablation success? CASTLE-AF Primary Endpoint All-cause mortality Worsening heart failure admissions Secondary Endpoints All-cause mortality Worsening

More information

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage

More information

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical

More information

La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole

La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole La strategia diagnostica: il monitoraggio ecg prolungato Michele Brignole ECG monitoring and syncope In-hospital monitoring Holter Monitoring External loop recorder Remote (at home) telemetry Implantable

More information

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario, Canada Chair,

More information

Rebuttal. Jerónimo Farré MD 2010

Rebuttal. Jerónimo Farré MD 2010 Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF

More information

Is Stroke Frequency Declining?

Is Stroke Frequency Declining? Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac

More information

PFO Management update

PFO Management update PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO

More information

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

Spontaneous Atrial Fibrillation and Noacs and Reversal agents Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial

More information

FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M.

FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M. FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M. Bufalini - Cesena FORAME OVALE PERVIO ICTUS CRIPTOGENETICO FORAME OVALE PERVIO

More information

Fibrillazione atriale: è sempre necessario ricercarla, e come?

Fibrillazione atriale: è sempre necessario ricercarla, e come? Fibrillazione atriale: è sempre necessario ricercarla, e come? Domenico Prisco DMSC Università di Firenze SOD Medicina Interna Interdisciplinare AOU Careggi Firenze 23-10-2018 Disclosure Fees for lectures

More information

AF monitoring and stroke: XPECT & REVEAL LINQ. Helmut Pürerfellner, Linz, Austria

AF monitoring and stroke: XPECT & REVEAL LINQ. Helmut Pürerfellner, Linz, Austria AF monitoring and stroke: XPECT & REVEAL LINQ Helmut Pürerfellner, Linz, Austria 2 Medtronic Confidential 3 Circ Arrhythm Electrophysiol 2010;3:141-47 Reveal XT versus LINQ 5 Parameter Reveal XT Reveal

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure

More information

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)

More information

Permanent foramen ovale: when to close?

Permanent foramen ovale: when to close? Permanent foramen ovale: when to close? Pierre Amarenco INSERM U-698 and Denis Diderot University - Paris VII Department of Neurology and Stroke Center Bichat hospital, Paris, France PFO - Pathology TEE

More information

Cardiac Electrophysiology

Cardiac Electrophysiology Cardiac Electrophysiology Tamara Langeberg, CNP Minneapolis Heart Institute Cardiac Electrophysiology February 27, 2018 Disclosures None 2 Objectives Rhythm identification Identify indications for cardiac

More information

Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC

Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in

More information

REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS

REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS Reveal LINQ TM Insertable Cardiac Monitoring System Are You Looking Long Enough? ONE-THIRD OF ISCHEMIC STROKES ARE CRYPTOGENIC (UNEXPLAINED) 1-6 HOW DO YOU

More information

Stroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow

Stroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia

More information

Critical Review Form Therapy

Critical Review Form Therapy Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of

More information

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria

More information

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude

More information

CRYPTOGENIC STROKE. Reveal LINQ TM THERAPY AWARENESS PRESENTATION

CRYPTOGENIC STROKE. Reveal LINQ TM THERAPY AWARENESS PRESENTATION CRYPTOGENIC STROKE Reveal LINQ TM Insertable Insertable Cardiac Cardiac Monitoring Monitoring System System THERAPY AWARENESS PRESENTATION AGENDA Epidemiology Diagnosis & Monitoring Strategies Evidence

More information

» A new drug s trial

» A new drug s trial » A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause

More information

Diagnostic and therapeutic management of the patient with syncope M. Brignole Arrhythmologic Centre and Syncope Unit Lavagna, Italy

Diagnostic and therapeutic management of the patient with syncope M. Brignole Arrhythmologic Centre and Syncope Unit Lavagna, Italy Diagnostic and therapeutic management of the patient with syncope M. Brignole Arrhythmologic Centre and Syncope Unit Lavagna, Italy Eur Heart J. 2009 Nov;30(21):2631-71 Available on www.escardio.org/guidelines

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ambulatory Event Monitors and Mobile

More information

Coagulation and ischaemic stroke

Coagulation and ischaemic stroke ESC Council on Stroke ESC Heart & Brain Workshop Prague, January 2018 Coagulation and ischaemic stroke Wolfram Doehner, PD, PhD Center for Stroke Research Berlin & Department of Cardiology, Campus Virchow

More information

Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα

Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα 2015-2016 Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received

More information

Atrial fibrillation and advanced age

Atrial fibrillation and advanced age Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ambulatory_event_monitors 10/2000 4/2017 4/2018 5/2017 Description of Procedure or Service There are a wide

More information

Management of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim

Management of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9

More information

Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring

Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring SAGE-Hindawi Access to Research Stroke Research and Treatment Volume 2011, Article ID 172074, 5 pages doi:10.4061/2011/172074 Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Strokes

More information

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor

More information

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past

More information

Controversies in Risk Stratification

Controversies in Risk Stratification Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?

More information

Embolinen aivoinfarkti vailla

Embolinen aivoinfarkti vailla Embolinen aivoinfarkti vailla syytä (ESUS) Neurologipäivät 2.11.2017 Jukka Putaala, vsel HYKS 1 Disclosures Research grant Helsinki and Uusimaa Hospital District, Academy of Finland, Finnish Funding Agency

More information

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring Catheter Ablation of Atrial Fibrillation: State of the Art Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring Dipen Shah Service de Cardiologie Hospital Cantonal de Genève

More information

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fabrizio Ammirati Dipartimento Medicina UOC Cardiologia Ospedale GB Grassi ASL Roma 3 Sept 2013 Patients

More information

DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending

DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the

More information

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director

More information

CLINICAL FEATURES THAT SUPPORT ATHEROSCLEROTIC STROKE 1. cerebral cortical impairment (aphasia, neglect, restricted motor involvement, etc.) or brain stem or cerebellar dysfunction 2. lacunar clinical

More information

POWERFUL CARDIAC MONITORING

POWERFUL CARDIAC MONITORING POWERFUL CARDIAC MONITORING Indications, Guidelines, Clinical Evidence, and Coding Overview for Diagnosing Suspected Arrhythmias and Monitoring Known A-Fib Reveal LINQ Insertable Cardiac Monitoring System

More information

Secondary Stroke Prevention: A Precautionary Tale

Secondary Stroke Prevention: A Precautionary Tale Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature

More information

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: Original Effective Date: MM.02.021 02/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/28/2017

More information

EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC

EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%

More information

Cardiovascular complica/ons a1er stroke

Cardiovascular complica/ons a1er stroke EANS ESC Council on Stroke joint session Venice, October 2017 Cardiovascular complica/ons a1er stroke Wolfram Doehner, PD, PhD Center for Stroke Research Berlin & Department of Cardiology, Campus Virchow

More information

Alan Barber. Professor of Clinical Neurology University of Auckland

Alan Barber. Professor of Clinical Neurology University of Auckland Alan Barber Professor of Clinical Neurology University of Auckland Presented with Non-fluent dysphasia R facial weakness Background Ischaemic heart disease Hypertension Hyperlipidemia L MCA branch

More information

Ictus criptogenetico: possiamo ridurre questa diagnosi?

Ictus criptogenetico: possiamo ridurre questa diagnosi? FIBRILLAZIONE ATRIALE Ictus criptogenetico: possiamo ridurre questa diagnosi? Maurizio Landolina MD, FESC Direttore U.O.C. Cardiologia, Ospedale Maggiore di Crema Disclosures Speakers bureau appointment

More information

Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy

Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy File Name: Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry File Code: UM.SPSVC.13 Origination: 10/2015 Last

More information

Primary Prevention of Stroke

Primary Prevention of Stroke Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for

More information

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: 2.02.08 Last Review: 9/2018 Origination: 11/2002 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Fibrillazione atriale e scompenso: come interrompere il circolo vizioso.

Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza

More information

Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico

Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Imagiologia na Fibrilhac ão Auricular Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Mª João Andrade Diagnosis and timely detection of atrial fibrillation Echo-machines

More information

ECTOPIC BEATS: HOW MANY COUNT?

ECTOPIC BEATS: HOW MANY COUNT? ECTOPIC BEATS: HOW MANY COUNT? Rupert FG Simpson, 1 Jessica Langtree, 2 *Andrew RJ Mitchell 2 1. King s College Hospital, London, UK 2. Jersey General Hospital, Jersey, UK *Correspondence to mail@jerseycardiologist.com

More information

Fibrillazione atriale subclinica e rischio di ictus ischemico

Fibrillazione atriale subclinica e rischio di ictus ischemico Fibrillazione atriale subclinica e rischio di ictus ischemico Background 25% of all ischemic strokes are cryptogenic, and subclinical atrial fibrilla;on (AF) is suspected to be a possible cause in many

More information

Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy

Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): 7/1/2002 Most Recent Review Date (Revised): 2/28/2018 Effective Date: 10/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS

More information

OAC after apparently successfull AF ablation: when, why, and how?

OAC after apparently successfull AF ablation: when, why, and how? Gulf EP Live 2015 - Dubai January 22-24 / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital,

More information